Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Bourgeon Capital Loves These Five Stocks. Should You?

Page 1 of 2

John A. Zaro, a Stanford graduate and a member of the New York Society of Security Analysts, founded Bourgeon Capital in 1999. Michael Keohane joined the fund in 2002 from SAC Capital to co-manage Bourgeon’s long/short hedge fund. The pair have done very well since then, by investing in quality companies and practicing solid risk management. Given that Bourgeon Capital recently disclosed its public equity portfolio in a 13F filing with the SEC, let’s take a closer look at Bourgeon Capital’s top picks of Plum Creek Timber Co. Inc. (NYSE:PCL)JPMorgan Chase & Co. (NYSE:JPM), Merck & Co., Inc. (NYSE:MRK),Schlumberger Limited. (NYSE:SLB), and Cisco Systems, Inc. (NASDAQ:CSCO).

Cisco Systems CSCO headquarters tech san jose networking corporation

Katherine Welles /

Most investors don’t understand hedge funds and indicators that are based on hedge funds’ activities. They ignore hedge funds because of their recent poor performance in the bull market. Our research indicates that hedge funds underperformed because they aren’t 100% long. Hedge fund fees are also very large compared to the returns generated and they reduce the net returns experienced by investors. We uncovered that hedge funds’ long positions actually outperformed the market. For instance the 15 most popular small-cap stocks among funds beat the S&P 500 Index by more than 53 percentage points since the end of August 2012. These stocks returned a cumulative of 102% vs. a 48.7% gain for the S&P 500 Index (see the details here). That’s why we believe investors should pay attention to what hedge funds are buying (rather than what their net returns are).

John Zaro
John Zaro
Bourgeon Capital

#5 Cisco Systems, Inc. (NASDAQ:CSCO)

Shares held (as of September 30): 166,700
Total Value (as of September 30): $4.38 million
Percent of Portfolio (as of September 30): 3.06%

Bourgeon Capital increased its position in Cisco Systems, Inc. (NASDAQ:CSCO) by 31% in the third quarter to 166,700 shares, as Cisco’s stock remains cheap, with a forward P/E of 11.66 versus the NASDAQ’s forward P/E of 19.85. Given Cisco’s growth opportunities in the internet of things, analysts are bullish, as 22 analysts have a ‘Buy’ rating, while just three have a ‘Sell’ rating, and nine have a ‘Hold’ rating. Overall, analysts have a consensus price target of $32.40 per share, suggesting upside of 13.24% on shares. Donald Yacktman‘s Yacktman Asset Management owned 42.1 million Cisco shares at the end of June.

Follow Cisco Systems Inc. (NASDAQ:CSCO)
Trade (NASDAQ:CSCO) Now!

#4 Merck & Co., Inc. (NYSE:MRK)

Shares held (as of September 30): 89,450
Total Value (as of September 30): $4.42 million
Percent of Portfolio (as of September 30): 3.08%

Bourgeon Capital upped its holding in Merck & Co., Inc. (NYSE:MRK) by 72% to 89,450 shares, good for 3.08% of the fund’s equity portfolio. The drug giant reported solid third quarter results, with earnings per share of $0.96 on revenues of $10.07 billion, beating earnings estimates by $0.04 per share and meeting revenue estimates. Guidance was pretty solid as well, with management expecting 2015 EPS of $1.64-to-$1.74, up from the previous $1.52-to-$1.71, along with 2015 revenues guidance of $39.2 billion-to-$39.8 billion, up on the lower end from the previous guidance of $38.3 billion-to-$39.8 billion. Given the forward P/E of 14.6 and dividend yield of 3.27%, shares look attractive for long-term shareholders.

Follow Merck & Co. Inc. (NYSE:MRK)
Trade (NYSE:MRK) Now!

Bourgeon Capital’s three most-loved stocks are looked at on the next page.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!